Inhibitex to Present at the 2010 Deutsche Bank BioFEST Conference on Tuesday, December 14th
December 13 2010 - 6:11PM
Business Wire
Inhibitex, Inc. (Nasdaq: INHX) today announced that Russell H.
Plumb, president and chief executive officer, will present an
overview of the company and its pipeline of differentiated
antiviral compounds at the Deutsche Bank BioFEST Conference
December 14, 2010 at 2:35 PM (ET). The conference is being held at
The Four Seasons Hotel in Boston, MA. The presentation will be
simultaneously webcast and can be accessed by visiting the
Investors section of the Inhibitex website
at www.inhibitex.com. Shortly following the live webcast, a
replay will also be available on the Company website.
About Inhibitex
Inhibitex, Inc., a biopharmaceutical company focused on
developing products to prevent and treat serious infectious
diseases. The Company’s pipeline includes FV-100, which is in Phase
II clinical development for the treatment of shingles, and INX-189,
a nucleotide polymerase inhibitor in development for the treatment
of chronic hepatitis C infections. The Company also has additional
HCV nucleotide polymerase inhibitors in preclinical development and
has licensed the use of its proprietary MSCRAMM® protein platform
to Pfizer for the development of staphylococcal vaccines. For
additional information about the Company, please visit
www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex,
Inc.
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Inhibitex, Inc. (MM) (NASDAQ:INHX)
Historical Stock Chart
From Jul 2023 to Jul 2024